Opendata, web and dolomites

TECNEC SIGNED

Preclinical concept validation of tumor endothelial cell metabolism for novel anti-angiogenic therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TECNEC project word cloud

Explore the words cloud of the TECNEC project. It provides you a very rough idea of what is the project "TECNEC" about.

data    analyze    rank    hypothesize    predict    negative    metabolomic    patients    bioinformatics    metabolic    endothelial    normal    blood    inhibition    models    block    shrna    lack    nothing    genome    vitro    necs    pioneered    treatment    silico    gems    inhibitors    therapy    differ    genes    isolated    horizons    transcriptomic    computational    promise    manner    nec    main    hyperactive    nourish    platform    background    though    cells    normalize    inhibiting    perform    validate    fuelling    dismissed    tumors    anti    network    mice    sufficient    efficacy    pioneering    biomex    followed    validation    methodology    versus    knockout    driving    screen    omics    activate    healthy    treatments    hyper    house    tumor    novelty    clinical    validated    rationale    cancer    tissue    preclinical    tecs    stimulate    modeling    promises    fundamentally    vessel    deregulated    demonstrated    conditional    vivo    metabolism    angiogenesis    tec    angiogenic    construct    biologically   

Project "TECNEC" data sheet

The following table provides information about the project.

Coordinator
VIB VZW 

Organization address
address: RIJVISSCHESTRAAT 120
city: ZWIJNAARDE - GENT
postcode: 9052
website: www.vib.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 2˙500˙000 €
 EC max contribution 2˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-ADG
 Funding Scheme ERC-ADG
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2022-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIB VZW BE (ZWIJNAARDE - GENT) coordinator 2˙500˙000.00

Map

 Project objective

MAIN GOAL: To characterize the metabolic changes, fuelling growth of tumor endothelial cells (TECs) versus normal healthy endothelial cells (NECs), and identify & validate metabolic genes, deregulated in TECs, as targets for anti-angiogenic cancer therapy.

BACKGROUND & RATIONALE: Tumors stimulate blood vessel growth (angiogenesis) to nourish cancer cells, but current anti-angiogenic treatments lack sufficient efficacy. NECs are widely used for anti-angiogenesis development, but TECs, the real target cells, have been dismissed, even though they differ fundamentally from NECs. We pioneered NEC metabolism research and demonstrated that inhibition of specific metabolic pathways can block angiogenesis. Nothing is however known on TEC metabolism. I hypothesize that TECs “hyper-activate” their metabolism in a tissue-specific manner, and that targeting TEC metabolism is a novel concept for inhibiting tumor angiogenesis.

METHODOLOGY: We will perform a transcriptomic and metabolomic analysis of TECs & NECs isolated from cancer patients, use an in-house developed bioinformatics platform (BIOMEX) to analyze the omics data in order to rank deregulated metabolic genes, and construct TEC-tailored genome scale metabolic network models (GEMs) allowing in silico computational modeling to predict metabolic targets that affect TEC but not NEC growth. The in vitro angiogenic activity of top targets will be biologically validated directly or after a negative selection shRNA-based screen, followed by validation in preclinical tumor models in vivo, using conditional knockout mice. All procedures are operational. Deliverables include in vivo validated metabolic targets, driving tumor angiogenesis.

NOVELTY, OVERALL & CLINICAL IMPACT: These pioneering studies on TEC metabolism promise to open up new horizons/opportunities for cancer research. Treatment with inhibitors of the validated targets promises to normalize hyperactive TEC metabolism as a novel anti-angiogenic cancer therapy.

 Publications

year authors and title journal last update
List of publications.
2018 Shawez Khan, Federico Taverna, Katerina Rohlenova, Lucas Treps, Vincent Geldhof, Laura de Rooij, Liliana Sokol, Andreas Pircher, Lena-Christin Conradi, Joanna Kalucka, Luc Schoonjans, Guy Eelen, Mieke Dewerchin, Tobias Karakach, Xuri Li, Jermaine Goveia, Peter Carmeliet
EndoDB: a database of endothelial cell transcriptomics data
published pages: D736-D744, ISSN: 0305-1048, DOI: 10.1093/nar/gky997
Nucleic Acids Research 47/D1 2019-09-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TECNEC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TECNEC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More